Literature DB >> 33664900

Distinctively different predictors for long-term outcomes between responders and nonresponders who underwent cardiac resynchronization therapy.

Kunio Yufu1, Ichitaro Abe1, Hidekazu Kondo1, Shotaro Saito1, Akira Fukui1, Norihiro Okada1, Hidefumi Akioka1, Tetsuji Shinohara1, Yasushi Teshima1, Mikiko Nakagawa1, Naohiko Takahashi1.   

Abstract

BACKGROUND: It is common to develop heart failure (HF) events even in respondents to cardiac resynchronization therapy (CRT) during a long-term observation period. We investigated the predictors for long-term outcome in responders in comparison with nonresponders in patients diagnosed with HF along with implanted CRT.
METHODS: We enrolled 133 consecutive patients (mean age, 70 ± 10 years; 72 males) implanted with CRT from April 2010 to July 2019. Accurate follow-up information (mean follow-up period, 983 ± 801 days) was obtained from 66 responders and 53 nonresponders.
RESULTS: Kaplan-Meier event-free curves showed that major adverse cerebral and cardiovascular event (MACCE)-free ratio was significantly lower as the stage of renal function progresses (log rank, 19.5; P < .0001). The baseline estimated glomerular filtration rate (e-GFR) before CRT was not significantly different between nonresponders and responders. The e-GFR after judgment of CRT response was lower in patients with MACCEs than those without. Cox proportional hazards regression analysis revealed that low baseline e-GFR before CRT and after judgment of CRT response was closely related with MACCEs in responders, but not in nonresponders. The survival rate in responders without MACCEs assessed using Kaplan-Meier analysis was significantly larger in the preserved e-GFR (baseline value before CRT, >44 mL/min/1.73 m2) group than in the depressed group (log rank, 20.29; P < .0001).
CONCLUSION: We demonstrate that the factors for MACCEs during long follow-up periods were distinctively different between responders and nonresponders. Patients with depressed e-GFRs are suggested to have poor prognosis even if they are responders to CRT.
© 2020 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society.

Entities:  

Keywords:  cardiac resynchronization therapy; heart failure; long‐term outcome; renal function; responder

Year:  2020        PMID: 33664900      PMCID: PMC7896449          DOI: 10.1002/joa3.12447

Source DB:  PubMed          Journal:  J Arrhythm        ISSN: 1880-4276


  19 in total

1.  Cardiac resynchronization in chronic heart failure.

Authors:  William T Abraham; Westby G Fisher; Andrew L Smith; David B Delurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

2.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

Authors:  Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

Review 3.  Cardio-Pulmonary-Renal Interactions: A Multidisciplinary Approach.

Authors:  Faeq Husain-Syed; Peter A McCullough; Horst-Walter Birk; Matthias Renker; Alessandra Brocca; Werner Seeger; Claudio Ronco
Journal:  J Am Coll Cardiol       Date:  2015-06-09       Impact factor: 24.094

4.  Duration of reverse remodeling response to cardiac resynchronization therapy: Rates, predictors, and clinical outcomes.

Authors:  Takafumi Oka; Koichi Inoue; Koji Tanaka; Yuko Toyoshima; Takaaki Isshiki; Takeshi Kimura; Masakiyo Nobuyoshi; Satoshi Shizuta; Takeshi Arita; Satoki Fujii; Katsuomi Iwakura; Kenshi Fujii; Kenji Ando
Journal:  Int J Cardiol       Date:  2017-05-12       Impact factor: 4.164

5.  Guidelines for Non-Pharmacotherapy of Cardiac Arrhythmias (JCS 2011).

Authors: 
Journal:  Circ J       Date:  2012-11-17       Impact factor: 2.993

6.  Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure.

Authors:  M Packer
Journal:  J Card Fail       Date:  2001-06       Impact factor: 5.712

7.  Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study.

Authors:  Jonathan C Hsu; Scott D Solomon; Mikhail Bourgoun; Scott McNitt; Ilan Goldenberg; Helmut Klein; Arthur J Moss; Elyse Foster
Journal:  J Am Coll Cardiol       Date:  2012-06-19       Impact factor: 24.094

8.  Results of the Predictors of Response to CRT (PROSPECT) trial.

Authors:  Eugene S Chung; Angel R Leon; Luigi Tavazzi; Jing-Ping Sun; Petros Nihoyannopoulos; John Merlino; William T Abraham; Stefano Ghio; Christophe Leclercq; Jeroen J Bax; Cheuk-Man Yu; John Gorcsan; Martin St John Sutton; Johan De Sutter; Jaime Murillo
Journal:  Circulation       Date:  2008-05-05       Impact factor: 29.690

Review 9.  Cardiorenal syndrome.

Authors:  Claudio Ronco; Mikko Haapio; Andrew A House; Nagesh Anavekar; Rinaldo Bellomo
Journal:  J Am Coll Cardiol       Date:  2008-11-04       Impact factor: 24.094

10.  Volumetric Response beyond Six Months of Cardiac Resynchronization Therapy and Clinical Outcome.

Authors:  Jetske van 't Sant; Aernoud T L Fiolet; Iris A H ter Horst; Maarten J Cramer; Mirjam H Mastenbroek; Wouter M van Everdingen; Thomas P Mast; Pieter A Doevendans; Henneke Versteeg; Mathias Meine
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.